461 related articles for article (PubMed ID: 9820264)
21. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
Sökeland J
BJU Int; 2000 Sep; 86(4):439-42. PubMed ID: 10971268
[TBL] [Abstract][Full Text] [Related]
22. Microwave thermotherapy for benign prostatic hyperplasia.
Hoffman RM; Monga M; Elliot SP; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD004135. PubMed ID: 17943811
[TBL] [Abstract][Full Text] [Related]
23. Microwave thermotherapy for benign prostatic hyperplasia.
Hoffman RM; Monga M; Elliott SP; Macdonald R; Langsjoen J; Tacklind J; Wilt TJ
Cochrane Database Syst Rev; 2012 Sep; (9):CD004135. PubMed ID: 22972068
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Ye Z; Huang J; Zhou L; Chen S; Wang Z; Ma L; Wang D; Wang G; Wang S; Liang C; Qiu S; Gu X; Liu J; Weng Z; Wu C; Wei Q; Xie L; Wu W; Cheng Y; Hu J; Wang Z; Zeng X
Urology; 2019 Jul; 129():172-179. PubMed ID: 30880074
[TBL] [Abstract][Full Text] [Related]
25. Hexanic Extract of Serenoa repens (Permixon
Blair HA
Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
[TBL] [Abstract][Full Text] [Related]
26. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials.
Russo GI; Scandura C; Di Mauro M; Cacciamani G; Albersen M; Hatzichristodoulou G; Fode M; Capogrosso P; Cimino S; Marcelissen T; Cornu JN; Gacci M; Minervini A; Cocci A;
Eur Urol Focus; 2021 Mar; 7(2):420-431. PubMed ID: 31952967
[TBL] [Abstract][Full Text] [Related]
27. Serenoa repens (saw palmetto): a systematic review of adverse events.
Agbabiaka TB; Pittler MH; Wider B; Ernst E
Drug Saf; 2009; 32(8):637-47. PubMed ID: 19591529
[TBL] [Abstract][Full Text] [Related]
28. Terazosin for benign prostatic hyperplasia.
Wilt TJ; Howe RW; Rutks IR; MacDonald R
Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
[TBL] [Abstract][Full Text] [Related]
29. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia.
MacDonald R; Ishani A; Rutks I; Wilt TJ
BJU Int; 2000 May; 85(7):836-41. PubMed ID: 10792162
[TBL] [Abstract][Full Text] [Related]
30. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
MacDonald R; Wilt TJ; Howe RW
BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
[TBL] [Abstract][Full Text] [Related]
31. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.
Cicero AFG; Allkanjari O; Busetto GM; Cai T; Larganà G; Magri V; Perletti G; Robustelli Della Cuna FS; Russo GI; Stamatiou K; Trinchieri A; Vitalone A
Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577095
[TBL] [Abstract][Full Text] [Related]
32. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
[TBL] [Abstract][Full Text] [Related]
33. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials.
Boyle P; Gould AL; Roehrborn CG
Urology; 1996 Sep; 48(3):398-405. PubMed ID: 8804493
[TBL] [Abstract][Full Text] [Related]
34. Comparison of
Cai T; Cui Y; Yu S; Li Q; Zhou Z; Gao Z
Am J Mens Health; 2020; 14(2):1557988320905407. PubMed ID: 32274957
[TBL] [Abstract][Full Text] [Related]
35. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
Wilt TJ; Howe RW; Rutks I; Macdonald R
Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD003851. PubMed ID: 21901686
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
Zlotta AR; Teillac P; Raynaud JP; Schulman CC
Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
[TBL] [Abstract][Full Text] [Related]
37. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
Wilt TJ; Howe W; MacDonald R
BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101
[TBL] [Abstract][Full Text] [Related]
38. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.
Barry MJ; Meleth S; Lee JY; Kreder KJ; Avins AL; Nickel JC; Roehrborn CG; Crawford ED; Foster HE; Kaplan SA; McCullough A; Andriole GL; Naslund MJ; Williams OD; Kusek JW; Meyers CM; Betz JM; Cantor A; McVary KT;
JAMA; 2011 Sep; 306(12):1344-51. PubMed ID: 21954478
[TBL] [Abstract][Full Text] [Related]
39. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
40. Beta-sitosterols for benign prostatic hyperplasia.
Wilt T; Ishani A; MacDonald R; Stark G; Mulrow C; Lau J
Cochrane Database Syst Rev; 2000; 1999(2):CD001043. PubMed ID: 10796740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
